On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
BUSINESS
Japan Ethical Drug Sales Slip 1.1% in November 2019: Crecon
Japan’s ethical drug sales edged down 1.1% in November 2019 versus the same month the previous year on a wholesaler shipment basis, according to a flash report released by Crecon Research & Consulting. November last year had one less business…
To read the full story
BUSINESS
- Yescarta Approved in Japan as 2nd CAR-T Cell Therapy
January 22, 2021
- Kyowa Pharma Controlling Shipments of 4 Generics on Recalls, COVID-19
January 22, 2021
- Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
- Taisho Kicks Off Japan PIII for Lusefi in Pediatric Type 2 Diabetes
January 22, 2021
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…